Treatment failure with new hepatitis C drugs

Author： Soriano Vincent   Vispo Eugenia   Poveda Eva   Labarga Pablo   Barreiro Pablo  

Publisher： Informa Healthcare

ISSN： 1465-6566

Source： Expert Opinion on Pharmacotherapy, Vol.13, Iss.3, 2012-02, pp. : 313-323

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Pharmacokinetics of new oral hepatitis C antiviral drugs

By Vispo Eugenia   Barreiro Pablo   Soriano Vicente  

Expert Opinion on Drug Metabolism and Toxicology, Vol. 9, Iss. 1, 2013-01 ,pp. : 5-16

Informa Healthcare

Access to resources Recommend Favorite

New Therapies for the Treatment of Chronic Hepatitis C

By  

Current Pharmaceutical Design, Vol. 8, Iss. 11, 2002-05 ,pp. : 959-966

Bentham Science Publishers

Access to resources Recommend Favorite

Emerging drugs for hepatitis C

By Soriano Vincent   Madejon Antonio   Vispo Eugenia   Labarga Pablo   Garcia-Samaniego Javier   Martin-Carbonero Luz   Sheldon Julie   Bottecchia Marcelle   Tuma Paula   Barreiro Pablo  

Expert Opinion on Emerging Drugs, Vol. 13, Iss. 1, 2008-03 ,pp. : 1-19

Informa Healthcare

Access to resources Recommend Favorite

Drugs in Development for Hepatitis C

By Stauber Rudolf E.  

Drugs, Vol. 68, Iss. 10, 2008-01 ,pp. : 1347-1359

Adis International

Access to resources Recommend Favorite

Telaprevir for the treatment of hepatitis C

By Forestier Nicole   Zeuzem Stefan  

Expert Opinion on Pharmacotherapy, Vol. 13, Iss. 4, 2012-03 ,pp. : 593-606

Informa Healthcare

Access to resources Recommend Favorite